Skip to main content
. 2020 Nov 24;4(22):5836–5845. doi: 10.1182/bloodadvances.2020002872

Table 2.

Baseline characteristics stratified by renal outcome in patients in the intensive and nonintensive pathway of the Myeloma XI trial

Intensive pathway Nonintensive pathway
Characteristic Decline in eGFR (≥25%) No change in eGFR (<25%) Improvement in eGFR (≥25%) P Decline in eGFR (≥25%) No change in eGFR (<25%) Improvement in eGFR (≥25%) P
N (%) 204 (14) 905 (62) 341 (23.5) 178 (20) 545 (62) 161 (18)
Age, y 66 (70-59) 65 (70-58) 66 (70-60) .184 78 (75-82) 78 (75-82) 78 (75-82) .706
 Median (IQR)
Baseline GFR, median (IQR), mL per min per 1.73 m2 80 (68-90) 75 (62-89) 51 (38-59.5) <.001 72 (58-87) 62 (48-77) 45 (33-57) <.001
12-mo GFR, median (IQR), mL per min per 1.73 m2 51 (43-57) 73 (60-89) 76 (60-90) <.001 44 (35-52) 60 (47-76) 67 (51-83) <.001
Baseline dFLC, n (%), mg <.001 .07
 <500 142 (70) 575 (64) 163 (48) 114 (64) 332 (61) 86 (53)
 500-1000 25 (12) 143 (16) 51 (15) 27 (15) 86 (16) 20 (12)
 >1000 36 (18) 181 (20) 124 (37) 36 (20) 124 (23) 55 (34)
 Missing 1 (0.5) 6 (0.7) 3 (0.9) 1 (0.6) 3 (0.6)
Baseline dFLC κ, median (IQR), mg/L (in κ patients) 241 (26-637) 264 (37-817) 426 (83-1531) <.001 240 (33-781) 374 (80-1027) 477 (103-1483) .017
Baseline dFLC λ, median (IQR), mg/L (in λ patients) 289 (49-694) 294 (47-801) 689 (174-2629) <.001 213 (25-782) 279 (47-755) 450 (131-2131) .07
dFLC response, n (%) .001 .002
 <50% 9 (4.4) 15 (1.6) 6 (1.8) 28 (15.6) 48 (8.7) 11 (6.8)
 50%-90% 9 (4.4) 58 (6.4) 17 (5) 28 (15.7) 128 (23.5) 41 (25.5)
 >90% 109 (53.4) 516 (57) 236 (69.2) 57 (32) 216 (39.6) 72 (44.7)
 Baseline dFLC <100 75 (37) 310 (34) 79 (23) 63 (35) 152 (27.8) 36 (22.3)
 Missing 2 (1) 6 (0.66) 3 (0.9) 2 (1) 1 (0.1) 1 (0.6)

Boldface P values signify statistical significance (P < .05).